Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Case report

Candidiasis caused by Candida kefyr in a neonate: Case report

Authors: Stefan Weichert, Konrad Reinshagen, Katrin Zahn, Gernot Geginat, Annebärbel Dietz, Anna Kristina Kilian, Horst Schroten, Tobias Tenenbaum

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Systemic Candidia infections are of major concern in neonates, especially in those with risk factors such as longer use of broad spectrum antibiotics. Recent studies showed that also term babies with underlying gastrointestinal or urinary tract abnormalities are much more prone to systemic Candida infection. We report a very rare case of candidiasis caused by Candida kefyr in a term neonate.

Case Presentation

Renal agenesis on the left side was diagnosed antenatally and anal atresia postnatally. Moreover, a vesico-ureteral-reflux (VUR) grade V was detected by cystography. The first surgical procedure, creating a protective colostoma, was uneventful. Afterwards our patient developed urosepsis caused by Enterococcus faecalis and was treated with piperacillin. The child improved initially, but deteriorated again. A further urine analysis revealed Candida kefyr in a significant number. As antibiotic resistance data about this non-albicans Candida species are limited, we started liposomal amphotericin B (AMB), but later changed to fluconazole after receiving the antibiogram. Candiduria persisted and abdominal imaging showed a Candida pyelonephritis. Since high grade reflux was prevalent we instilled AMB into the child's bladder as a therapeutic approach. While undergoing surgery (creating a neo-rectum) a recto-vesical fistula could be shown and subsequently was resected. The child recovered completely under systemic fluconazole therapy over 3 months.

Conclusions

Candidiasis is still of major concern in neonates with accompanying risk factors. As clinicians are confronted with an increasing number of non-albicans Candida species, knowledge about these pathogens and their sensitivities is of major importance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE: Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004, 23: 635-641. 10.1097/01.inf.0000128781.77600.6f.CrossRefPubMed Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE: Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004, 23: 635-641. 10.1097/01.inf.0000128781.77600.6f.CrossRefPubMed
2.
go back to reference Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, Tridapalli E, Corona G, Giovannozzi C, Farina D, Arisio R, Merletti F, Maule M, Mosca F, Pedicino R, Stronati M, Mostert M, Gomirato G: A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007, 356: 2483-2495. 10.1056/NEJMoa065733.CrossRefPubMed Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, Tridapalli E, Corona G, Giovannozzi C, Farina D, Arisio R, Merletti F, Maule M, Mosca F, Pedicino R, Stronati M, Mostert M, Gomirato G: A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007, 356: 2483-2495. 10.1056/NEJMoa065733.CrossRefPubMed
3.
go back to reference Neu N, Malik M, Lunding A, Whittier S, Alba L, Kubin C, Saiman L: Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J. 2009, 28: 806-809. 10.1097/INF.0b013e3181a0d78d.CrossRefPubMed Neu N, Malik M, Lunding A, Whittier S, Alba L, Kubin C, Saiman L: Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J. 2009, 28: 806-809. 10.1097/INF.0b013e3181a0d78d.CrossRefPubMed
4.
go back to reference Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010, 48: 1366-1377. 10.1128/JCM.02117-09.CrossRefPubMedPubMedCentral Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010, 48: 1366-1377. 10.1128/JCM.02117-09.CrossRefPubMedPubMedCentral
5.
go back to reference White TJ, Bruns T, Lee S, Taylor JW: Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR Protocols: A Guide to Methods and Applications. Edited by: Innis MA, Gelfand DH, Sninsky JJ, White TJ. 1990, New York: Academic, 315-322. White TJ, Bruns T, Lee S, Taylor JW: Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR Protocols: A Guide to Methods and Applications. Edited by: Innis MA, Gelfand DH, Sninsky JJ, White TJ. 1990, New York: Academic, 315-322.
6.
go back to reference Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R: Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004, 23: 317-322. 10.1007/s10096-004-1103-y.CrossRefPubMed Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R: Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004, 23: 317-322. 10.1007/s10096-004-1103-y.CrossRefPubMed
7.
go back to reference Gomez-Lopez A, Pan D, Cuesta I, Alastruey-Izquierdo A, Rodriguez-Tudela JL, Cuenca-Estrella M: Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis. 2010, 66: 116-119. 10.1016/j.diagmicrobio.2009.06.007.CrossRefPubMed Gomez-Lopez A, Pan D, Cuesta I, Alastruey-Izquierdo A, Rodriguez-Tudela JL, Cuenca-Estrella M: Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis. 2010, 66: 116-119. 10.1016/j.diagmicrobio.2009.06.007.CrossRefPubMed
8.
go back to reference Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN: In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003, 41: 78-83. 10.1128/JCM.41.1.78-83.2003.CrossRefPubMedPubMedCentral Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN: In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003, 41: 78-83. 10.1128/JCM.41.1.78-83.2003.CrossRefPubMedPubMedCentral
9.
go back to reference Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U: Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007, 60: 424-428. 10.1093/jac/dkm145.CrossRefPubMed Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U: Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007, 60: 424-428. 10.1093/jac/dkm145.CrossRefPubMed
10.
go back to reference Mirdha BR, Sethi S, Banerjee U: Prevalence of fungal species in patients with candiduria. Indian J Med Res. 1998, 107: 90-93.PubMed Mirdha BR, Sethi S, Banerjee U: Prevalence of fungal species in patients with candiduria. Indian J Med Res. 1998, 107: 90-93.PubMed
11.
go back to reference Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care Med. 2006, 34: 857-863. 10.1097/01.CCM.0000201897.78123.44.CrossRefPubMed Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care Med. 2006, 34: 857-863. 10.1097/01.CCM.0000201897.78123.44.CrossRefPubMed
12.
go back to reference Robinson JL, Davies HD, Barton M, O'Brien K, Simpson K, Asztalos E, Synnes A, Rubin E, Le Saux N, Hui C, Langley JM, Sauve R, de Repentigny L, Kovacs L, Tan B, Richardson SE: Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis. 2009, 9: 183-10.1186/1471-2334-9-183.CrossRefPubMedPubMedCentral Robinson JL, Davies HD, Barton M, O'Brien K, Simpson K, Asztalos E, Synnes A, Rubin E, Le Saux N, Hui C, Langley JM, Sauve R, de Repentigny L, Kovacs L, Tan B, Richardson SE: Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis. 2009, 9: 183-10.1186/1471-2334-9-183.CrossRefPubMedPubMedCentral
13.
go back to reference Lundstrom T, Sobel J: Nosocomial candiduria: a review. Clin Infect Dis. 2001, 32: 1602-1607. 10.1086/320531.CrossRefPubMed Lundstrom T, Sobel J: Nosocomial candiduria: a review. Clin Infect Dis. 2001, 32: 1602-1607. 10.1086/320531.CrossRefPubMed
14.
go back to reference Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jordá R, Nolla-Salas J, León-Regidor MA, EPCAN Study Group: Economic impact of candida colonization and candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004, 23: 323-330. 10.1007/s10096-004-1104-x.CrossRefPubMed Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jordá R, Nolla-Salas J, León-Regidor MA, EPCAN Study Group: Economic impact of candida colonization and candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004, 23: 323-330. 10.1007/s10096-004-1104-x.CrossRefPubMed
15.
go back to reference Altuncu E, Bilgen H, Cerikçioğlu N, Ilki A, Ulger N, Bakır M, Akman I, Ozek E: Neonatal Candida infections and the antifungal susceptibilities of the related Candida species. Mikrobiyol Bul. 2010, 44: 593-603.PubMed Altuncu E, Bilgen H, Cerikçioğlu N, Ilki A, Ulger N, Bakır M, Akman I, Ozek E: Neonatal Candida infections and the antifungal susceptibilities of the related Candida species. Mikrobiyol Bul. 2010, 44: 593-603.PubMed
16.
go back to reference Rani R, Mohapatra NP, Mehta G, Randhawa VS: Changing trends of Candida species in neonatal septicaemia in a tertiary North Indian hospital. Indian J Med Microbiol. 2002, 20: 42-44.PubMed Rani R, Mohapatra NP, Mehta G, Randhawa VS: Changing trends of Candida species in neonatal septicaemia in a tertiary North Indian hospital. Indian J Med Microbiol. 2002, 20: 42-44.PubMed
17.
go back to reference Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, Hertenstein B, Ganser A: Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis. 2005, 41: 1365-1366. 10.1086/497079.CrossRefPubMed Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, Hertenstein B, Ganser A: Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis. 2005, 41: 1365-1366. 10.1086/497079.CrossRefPubMed
18.
go back to reference Chopra T, Bhargava A, Kumar S, Chopra A, Dhar S, Afonso L, Sobel JD: Candida kefyr endocarditis in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2010, 339: 188-189. 10.1097/MAJ.0b013e3181c0d945.CrossRefPubMed Chopra T, Bhargava A, Kumar S, Chopra A, Dhar S, Afonso L, Sobel JD: Candida kefyr endocarditis in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2010, 339: 188-189. 10.1097/MAJ.0b013e3181c0d945.CrossRefPubMed
19.
go back to reference Direkze S, Mansour M, Rodriguez-Justo M, Kibbler C, Gant V, Peggs KS: Candida kefyr fungal enteritis following autologous BMT. Bone Marrow Transplantation. 2011, doi:10.1038/bmt.2011.112 Direkze S, Mansour M, Rodriguez-Justo M, Kibbler C, Gant V, Peggs KS: Candida kefyr fungal enteritis following autologous BMT. Bone Marrow Transplantation. 2011, doi:10.1038/bmt.2011.112
20.
go back to reference Sendid B, Lacroix C, Bougnoux ME: Is Candida kefyr an emerging pathogen in patients with oncohematological diseases?. Clin Infect Dis. 2006, 43: 666-667. 10.1086/506573.CrossRefPubMed Sendid B, Lacroix C, Bougnoux ME: Is Candida kefyr an emerging pathogen in patients with oncohematological diseases?. Clin Infect Dis. 2006, 43: 666-667. 10.1086/506573.CrossRefPubMed
21.
go back to reference Valderrama MJ, de Silóniz MI, Gonzalo P, Peinado JM: A differential medium for the isolation of Kluyveromyces marxianus and Kluyveromyces lactis from dairy products. J Food Prot. 1999, 62: 189-193.PubMed Valderrama MJ, de Silóniz MI, Gonzalo P, Peinado JM: A differential medium for the isolation of Kluyveromyces marxianus and Kluyveromyces lactis from dairy products. J Food Prot. 1999, 62: 189-193.PubMed
Metadata
Title
Candidiasis caused by Candida kefyr in a neonate: Case report
Authors
Stefan Weichert
Konrad Reinshagen
Katrin Zahn
Gernot Geginat
Annebärbel Dietz
Anna Kristina Kilian
Horst Schroten
Tobias Tenenbaum
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-61

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.